These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 28240914)

  • 1. General Method to Determine the Flux of Charged Molecules through Nanopores Applied to β-Lactamase Inhibitors and OmpF.
    Ghai I; Pira A; Scorciapino MA; Bodrenko I; Benier L; Ceccarelli M; Winterhalter M; Wagner R
    J Phys Chem Lett; 2017 Mar; 8(6):1295-1301. PubMed ID: 28240914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing transport of charged β-lactamase inhibitors through OmpC, a membrane channel from E. coli.
    Ghai I; Winterhalter M; Wagner R
    Biochem Biophys Res Commun; 2017 Feb; 484(1):51-55. PubMed ID: 28109883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic properties of beta-lactamase inhibitors.
    de la Pena A; Derendorf H
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):63-75. PubMed ID: 10082170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
    Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
    Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
    J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.
    Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
    Int J Antimicrob Agents; 2017 Feb; 49(2):189-197. PubMed ID: 27988068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
    Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
    Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
    Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
    Guet-Revillet H; Tomini E; Emirian A; Join-Lambert O; Lécuyer H; Zahar JR; Jullien V
    Int J Antimicrob Agents; 2017 Jan; 49(1):62-66. PubMed ID: 27876276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability of piperacillin concentrations in relation to tazobactam concentrations in critically ill patients.
    Zander J; Döbbeler G; Nagel D; Scharf C; Huseyn-Zada M; Jung J; Frey L; Vogeser M; Zoller M
    Int J Antimicrob Agents; 2016 Oct; 48(4):435-9. PubMed ID: 27476810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment.
    Merdjan H; Tarral A; Das S; Li J
    J Clin Pharmacol; 2017 Feb; 57(2):211-218. PubMed ID: 27402250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinations.
    McLeod SM; Patey SA; Huband MD; Nichols WW
    Int J Antimicrob Agents; 2017 Apr; 49(4):437-442. PubMed ID: 28242258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
    Mischnik A; Baumert P; Hamprecht A; Rohde A; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
    Int J Antimicrob Agents; 2017 Feb; 49(2):239-242. PubMed ID: 27939093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Permeation of β-Lactamase Inhibitors through the General Porins of Gram-Negative Bacteria.
    Pira A; Scorciapino MA; Bodrenko IV; Bosin A; Acosta-Gutiérrez S; Ceccarelli M
    Molecules; 2020 Dec; 25(23):. PubMed ID: 33291474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.